CA-HALIO
16.11.2023 14:01:35 CET | Business Wire | Press release
HALIO, designer of the world’s fastest, most beautiful, eco-friendly, and technologically advanced electrochromic (smart) glass, and SKC Ltd., a leading company in the ESG Materials Solution industry based in South Korea, today announced that HALIO has raised up to $70M in funding from SKC to further market and develop the industry’s next generation of smart glass technology, focusing on energy savings, environmental impact, and creating beautiful facades, while enabling occupant wellness and comfort.
“This investment is expected to further expand our ESG strategy,” said SKC’s Vice President Junghwan Shin. “We strongly believe that HALIO has the most advanced smart glass technology that will significantly impact global energy savings and our environment,” emphasized Shin.
In conjunction with the funding announcement, HALIO also announced the appointment of Doug Schendt as the company's new CEO, replacing Bruce Sohn, who has served as CEO since 2020. Sohn is retiring after successfully leading the company through this latest milestone.
"I'm thrilled to take on this new role and lead HALIO into its next phase of growth," said Schendt. "Having previously led our Asia operations, I'm excited to now head HALIO globally. Bruce's vision and leadership have positioned us well, and I look forward to building on that strong foundation."
HALIO Smart Glass enables architects to design beautiful and elegant facades, supporting building owners’ pursuit of providing occupants with the most comfortable, productive, and healthy interior environments. HALIO’s Sky Camera, tint algorithms, and control automation, coupled with the industry’s fastest switching speed (within seconds), make HALIO the only smart glass solution that truly optimizes daylight control and solar heat gain management in real-time.
HALIO's smart glass technology reduces a building's operational energy use by up to 22%. It decreases peak demand by 25%, which is vital in balancing overstressed power grids (Red Car Analytics - Energy Efficiency Analysis of HALIO, Nov 2019). With countries now targeting buildings as major energy users, regulations increasingly require more efficient facades. Additionally, new incentives like the U.S. Investment Tax Credit reward owners for adding energy-saving solutions like HALIO Smart Glass.
"This new capital enables us to accelerate innovation in our smart glass technology as well as expand our reach in key markets like Asia, Europe, and the Middle East," added Sohn. "This is an incredibly exciting time for HALIO. I'm proud of what we've accomplished and am confident that with Doug as CEO, the company is in great hands to continue our mission and bring our products to customers globally."
About HALIO
HALIO Smart Glass is the world’s fastest and most advanced electrochromic (smart glass) technology, enabling maximum control of daylight while optimizing energy savings by reducing solar heat gain and minimizing glare. Powered by HALIO windows and skylights are available directly from the HALIO and third-party fabricators, including Viracon and GLASSBEL, with various glass coatings and configurations. Beautiful buildings deserve beautiful facades. Find out more what HALIO can do for your next building project at www.halioinc.com.
About SKC
For the past 40 years, SKC has focused on developing materials to create a better world, positioning today as a ‘Materials Solution Company’. SKC has recently reorganized its business portfolio, centering around rechargeable batteries, semiconductors, and eco-friendly materials. Our goal is to provide new values to customers with state-of-the-art technology and earn support and trust from both customers and society, with the vision of becoming a ‘Global Major ESG Eco-Friendly Materials Solution Company’. SKC will continue to make ceaseless challenge and innovation. Learn more: http://www.skc.co.kr/eng/main/index.do
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116891065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom